文献速递细菌感染、耐药与抗菌药物

注射用磷霉素(ZTI-01)对比哌拉西林-他唑巴坦治疗复杂性尿路感染及急性肾盂肾炎:ZEUS 2/3期随机试验

Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.
PubMed 文献 · Clin Infect Dis · 2019-01-01

ZEUS试验将住院的复杂性尿路感染(cUTI)或急性肾盂肾炎(AP)成人随机分配接受ZTI-01 6g q8h或哌拉西林-他唑巴坦4.5g q8h静脉治疗7天。在微生物学改良意向治疗人群中,ZTI-01总体成功率64.7% vs 54.5%,达到非劣效主要终点,治疗差异10.2%(95%CI -0.4~20.8)。ZTI-01耐受良好,为严重革兰阴性感染提供了一种作用机制不同的新静脉治疗选择。

要点

  • ZTI-01 6g q8h治疗cUTI/AP的总体成功率非劣效于哌拉西林-他唑巴坦4.5g q8h。
  • 临床治愈率在两治疗组均较高且相似(90.8% vs 91.6%)。
  • ZTI-01耐受良好,多数不良事件轻微且短暂。

核心结论

  • ZTI-01对包括AP在内的cUTI有效,为严重革兰阴性感染提供了一种作用机制不同的新静脉治疗选择。

研究设计与样本

  • ZEUS为2/3期随机试验,将住院的疑似或微生物学确诊cUTI/AP成人按1:1随机分组。
  • ZTI-01组6g q8h静脉给药,哌拉西林-他唑巴坦组4.5g q8h静脉给药,固定疗程7天(不转换口服)。
  • 合并菌血症患者可延长至14天。
  • 共465例随机,ZTI-01组233例、哌拉西林-他唑巴坦组231例接受治疗。

主要发现

  • 微生物学改良意向治疗人群中,ZTI-01总体成功率64.7%(119/184)vs 哌拉西林-他唑巴坦54.5%(97/178),治疗差异10.2%(95%CI -0.4~20.8)。
  • 治愈访视(TOC,第19-21天)临床治愈率ZTI-01组90.8%(167/184)vs 哌拉西林-他唑巴坦组91.6%(163/178)。
  • 事后分析采用脉冲场凝胶电泳分型的独特病原体,m-MITT人群TOC总体成功率ZTI-01组69.0%(127/184)vs 哌拉西林-他唑巴坦组57.3%(102/178),差异11.7%(95%CI 1.3~22.1)。
  • ZTI-01耐受良好,大多数治疗中出现的不良事件(包括低钾血症和血清转氨酶升高)轻微且短暂。

关键数值与推荐

  • ZTI-01组给药方案:6g q8h静脉,固定7天,合并菌血症可延长至14天。
  • 哌拉西林-他唑巴坦组给药方案:4.5g q8h静脉,固定7天,合并菌血症可延长至14天。
  • 主要终点非劣效性在m-MITT人群评估,总体成功率ZTI-01组64.7% vs 哌拉西林-他唑巴坦组54.5%,治疗差异10.2%(95%CI -0.4~20.8)。

临床怎么用

  • 对于住院的cUTI/AP成人患者,ZTI-01 6g q8h静脉7天方案可作为哌拉西林-他唑巴坦的替代选择。
  • ZTI-01的作用机制不同于现有药物,可能对多重耐药革兰阴性病原体提供治疗选项。
  • 治疗期间需监测低钾血症和血清转氨酶,但多数事件轻微且短暂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ZTI-01 (fosfomycin for injection) is an epoxide antibiotic with a differentiated mechanism of action (MOA) inhibiting an early step in bacterial cell wall synthesis. ZTI-01 has broad in vitro spectrum of activity, including multidrug-resistant Gram-negative pathogens, and is being developed for treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) in the United States. METHODS: Hospitalized adults with suspected or microbiologically confirmed cUTI/AP were randomized 1:1 to 6 g ZTI-01 q8h or 4.5 g intravenous (IV) piperacillin-tazobactam (PIP-TAZ) q8h for a fixed 7-day course (no oral switch); patients with concomitant bacteremia could receive up to 14 days. RESULTS: Of 465 randomized patients, 233 and 231 were treated with ZTI-01 and PIP-TAZ, respectively. In the microbiologic modified intent-to-treat (m-MITT) population, ZTI-01 met the primary objective of noninferiority compared with PIP-TAZ with overall success rates of 64.7% (119/184 patients) vs 54.5% (97/178 patients), respectively; treatment difference was 10.2% (95% confidence interval [CI]: -0.4, 20.8). Clinical cure rates at test of cure (TOC, day 19-21) were high and similar between treatments (90.8% [167/184] vs 91.6% [163/178], respectively). In post hoc analysis using unique pathogens typed by pulsed-field gel electrophoresis, overall success rates at TOC in m-MITT were 69.0% (127/184) for ZTI-01 versus 57.3% (102/178) for PIP-TAZ (difference 11.7% 95% CI: 1.3, 22.1). ZTI-01 was well tolerated. Most treatment-emergent adverse events, including hypokalemia and elevated serum aminotransferases, were mild and transient. CONCLUSIONS: ZTI-01 was effective for treatment of cUTI including AP and offers a new IV therapeutic option with a differentiated MOA for patients with serious Gram-negative infections. CLINICAL TRIAL REGISTRATION: NCT02753946.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kaye KS, Rice LB, Dane AL, et al. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis. 2019. PMID: 30861061. doi:10.1093/cid/ciz181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。